StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Vertex Pharma (VRTX): Solid Beat And No Guidance Until PDUFA Date, PT To $197 - BofA
February 1, 2018 6:51 AM
BofA/Merrill Lynch analyst, Ying Huang, reiterated his Buy rating on shares of Vertex (NASDAQ: VRTX) and raised his price target ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst EPS View
Analyst PT Change
Next Articles
Vertex (VRTX) PT Raised to $200 at Baird; Triple Update and Strong Results
February 1, 2018 9:09 AM
Vertex (VRTX) PT Raised to $183 at UBS
February 1, 2018 9:08 AM
